Taysha Gene Therapies, Inc. (TSHA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Taysha Gene Therapies, Inc. (TSHA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 36/100 — a percentile rank of Taysha Gene Therapies, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $1.6B |
| P / S | 299.4× |
| EV / EBITDA | -8.0× |
| Gross margin | 100.0% |
| Operating margin | -2792.3% |
| Net margin | -2728.0% |
| Return on equity | -38.6% |
| ROIC | 811.2% |
| Revenue growth | -32.3% |
| Debt / equity | 0.1× |
| Dividend yield | 0.0% |
Is Taysha Gene Therapies, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from Taysha Gene Therapies, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact